Меню
Идёт набор NCT05128006

Direct-to-patient Teledermatology and Computer-assisted Diagnosis

Наблюдательное New Patient Use of Teledermatology Mobile App

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: New patient teledermatology visit.
Кому может быть актуально
Состояния в реестре: New Patient Use of Teledermatology Mobile App. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Improving Dermatology Access by Direct-to-Patient Teledermatology and Computer-Assisted Diagnosis

Обзор

This study will examine access to dermatology care. The operational partner will implement a direct-to-new patient teledermatology clinical care pathway while the research will study the effects of that implementation, use data associated with deployment to develop and test an Artificial Intelligence system, and understand key stakeholders' attitudes regarding and readiness for remote dermatology care.

Подробное описание

VA is uniquely positioned to develop and study direct-to-patient teledermatology in parallel with computer vision for skin disease. The following aims will assess the performance of these emerging patient-facing dermatology innovations and assess their ability to improve access to quality skin care VA-wide.

1. Assess the impact of direct-to-patient teledermatology on access and health system utilization. In collaboration with the VA operational partner, Office of Connected Care, the My VA Images app will be deployed to three VA facilities where the app will be introduced as an option to refer eligible new patients for dermatology consultation. Multiple access metrics, including time to consult completion and geographic distance traveled. will be measured in exposed patients and compared with patients referred to usual in-person and consultative teledermatology pathways. Facility-centric measures of access such as clinic appointment wait times and in-person dermatology clinic and community care utilization will also be measured. To better understand end-user experiences, the investigators will survey patients and staff at each study site to evaluate their satisfaction with My VA Images as well as the overall process. 2. Assess, refine and augment computer-assisted evaluation of patient-submitted images. An artificial intelligence-powered computer vision model, trained and validated on clinic-captured images of melanoma and nevi, will be tested and refined on patient-submitted teledermatology images from the My VA images app. The investigators will also extend the computer vision model by using all patient submissions to train and validate the model on a wider variety of skin diagnoses. Patient-submitted teledermatology images at study sites will be prospectively evaluated by the investigators' own computer vision model as well as by a commercial system currently available to VA clinicians and patients, and results will be compared with benchmark diagnoses to measure concordance across a range of diagnostic categories. 3. Assess readiness of VA and Veterans' acceptance to implement direct-to-patient care. The investigators will survey Veterans and key VA leadership and staff at three selected VA facilities, supplemented by interviews of key VA stakeholders, to understand patients' and organizational readiness, including facilitators and barriers, for transitioning to patient-facing technologies in general, and direct-to-patient dermatologic care in particular. National Veteran surveys, and VA Mobile Health user satisfaction data will help place local observations in perspective. Implementation and sustainability of the patient-facing teledermatology app technology will also be measured.

Вмешательства

  • Другое New patient teledermatology visit
    new patient teledermatology visits

Первичные конечные точки

  • New patient in-person dermatology visits [Срок оценки: 4 years]
  • Consult completion time [Срок оценки: 4 years]
  • Appointment completion time [Срок оценки: 4 years]
  • Travel distance for VA care [Срок оценки: 4 years]
  • Third next available dermatology clinic appt completion time [Срок оценки: 4 years]
  • New Patient Teledermatology encounters [Срок оценки: 4 years]
  • Organizational Readiness to implement mobile teledermatology for direct new patient care [Срок оценки: 4 years]
  • Readiness of Veterans to use mobile teledermatology for direct new patient care [Срок оценки: 4 years]
  • Patient Satisfaction of different types of dermatologic care [Срок оценки: 4 years]
  • Readiness of Veterans to use Artificial Intelligence for dermatologic care [Срок оценки: 4 years]
Вторичные конечные точки (2)
  • Scheduled compared to clinically indicated appointment date [Срок оценки: 4 years]
  • Whether patient had a no-show event for an intended encounter [Срок оценки: 4 years]

Критерии участия

Критерии включения

  • New patient referrals to dermatology at San Francisco, Decatur, and Aurora from 2021-2025

Критерии исключения

  • Patients who are not dermatology patients
  • Dermatology patients who are not seen at San Francisco, Decatur, and Aurora
  • Dermatology patients at San Francisco, Decatur, and Aurora who have visits only before 2021 or after 2025

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

США · 3 центра
  • San Francisco VA Medical Center, San Francisco, CA — San Francisco
  • Rocky Mountain Regional VA Medical Center, Aurora, CO — Aurora
  • Atlanta VA Medical and Rehab Center, Decatur, GA — Decatur

Идентификаторы

NCT: NCT05128006 · IIR 21-103 · HX003473

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗